



INTERNATIONAL RESEARCH CONFERENCE

With support from ESF

ESF-IfW Conference on The Global Health
Economy
The Global Organisation of Biomedical
Innovation: Funding, Intellectual
Property Rights, Incentives and the
Diffusion of New Technology


Hotel Kieler Yacht Club (KYC), Kiel • Germany
4-8 October 2007

Chair: **Frederic M. Scherer**, John F. Kennedy School of Government,
Harvard University, US

Vice-Chair: **M.N. Graham Dukes**, University of Oslo, NO

www.esf.org/conferences/07247

With support from **Fritz Thyssen Stiftung**
FÜR WISSENSCHAFTSFÖRDERUNG



www.esf.org

Final Programme

Thursday – 4 October

Late afternoon / early evening	Registration at the Hotel “Kieler Yacht Club” (Secretary’s desk)
19.30	Welcome Drink
20.00	Dinner

Friday – 5 October

09.00-09.15	Conference Opening Frederic M. Scherer , Harvard University, US M.N. Graham Dukes , University of Oslo, NO Michael Stolpe , Kiel Institute for the World Economy, DE
-------------	--

Session 1: Demand, Supply, Government Funding and Private Insurance in the Global Market for Biomedical Innovation

Chair: **M.N. Graham Dukes**, University of Oslo, NO

09.15-09.50	Félix Lobo Universidad Carlos III de Madrid, ES <i>Science and Regulation – How Market Regulations Increasingly Depend on Science. The Case of the European Union</i>
09.50-10.25	Frederic M. Scherer Harvard University, Cambridge, US <i>Coping with Uncertainty in Pharmaceutical Development</i>
10.25-11.00	Charles Abraham Yankah German Heart Institute Berlin, DE <i>The Role of Translational Medicine in Accelerating Biomedical Innovation</i>
11.00-11.30	Coffee break
11.30-12.05	Rainer Sauerborn University of Heidelberg, DE <i>The Optimal Financing and Organisation of Health Care in Low and Middle Income Countries</i>
12.05-12.20	Ayesha Aftab World Health Organization, Riwalpindi, PK <i>Health Care Responsive Budgeting – Evolving Linkages between Public and Private Investment</i>

12.20-12.50 **Carsten M.H. Claussen**
Evotec Technologies GmbH, Hamburg, DE
Session Discussion on Demand, Supply, Government Funding and Private Insurance in the Global Market for Biomedical Innovation

13.00 Lunch

Session 2: Intellectual Property Rights and International Trade

Chair: **Frederic M. Scherer**, Harvard University, US

14.30-15.10 **Ove Granstrand**
Chalmers University of Technology, Göteborg, SE
The Role of Intellectual Property Rights in Biomedical Innovation

15.10-15.50 **James Love**
Consumer Project for Technology, Washington DC, US
Prospects for a Global Treaty to Govern Biomedical Research

15.50-16.20 Coffee break

16.20-17.00 **Jayashree Watal**
WTO, Geneva, CH
The TRIPS Agreement and Public Health – with a Focus on the Paragraph 6 System of the Doha Declaration

17.00-17.20 **Naomi Hawkins**
The Ethox Centre, University of Oxford, UK
The Impact of Patents on the Translation of Research into Clinical Application in the Context of Genetic Diagnostics

17.20-17.40 **Daniel Maceira**
Center for the Study of State and Society, CEDES, Buenos Aires, AR
Pharmaceutical Product Regulation in Argentina – Organizational Structure and Comparative Performance

17.40-18.10 **Kathrin Adlkofer**
Norgenta, Life Science Nord, Hamburg, DE
Session Discussion on Intellectual Property Rights and International Trade

19.00-20.00 Dinner

20.00-21.30 Poster Session

Saturday – October 6

Session 3: The Social Returns to Biomedical Research

Chair: Dietmar Harhoff, University of Munich, DE

- 09.15-09.55 **Joseph diMasi**
Tufts University, Boston, UK
Trends in Post-approval Pharmaceutical R&D – Dissecting the Data on Line Extensions
- 09.55-10.35 **Frank R. Lichtenberg**
Columbia University, New York, US
International Medical Technology Diffusion
- 10.35-11.05 Coffee break
- 11.05-11.45 **Ronald J. Gilson**
Stanford University, US
Fostering Successful Venture Investing in Biotechnology – Lessons for Europe
- 11.45-12.20 **Rainer Sauerborn**
University of Heidelberg, DE
Session Discussion on The Social Returns to Biomedical Research

Session 4: The Fragile State of Europe's Biomedical Industry

Chair: Michael Stolpe, Kiel Institute for the World Economy, DE

- 12.20-13.00 **Liselotte Højgaard**
Rigshospitalet Copenhagen, DK, and Chair, European Medical Research Councils
Present Status and Future Strategy for Medical Research in Europe
- 13.00-14.15 Lunch
- 14.15-14.50 **Fabio Pammolli**
University of Florence, and Director, IMT Lucca Institute for Advanced Studies, IT
European Pharmaceutical Innovation and Regulatory Systems
- 14.50-15.25 **Dietmar Harhoff and Carolin Häußler**
University of Munich, DE
Comparing the German and the British Biotechnology Industries – Finance, Management and Regulation
- 15.25-16.00 **Maureen McKelvey**
Chalmers University of Technology, Göteborg, SE
Managing Bioengineering Companies – A European Perspective
- 16.00-16.30 Coffee Break
- 16.30-17.05 **Luigi Orsenigo**
University of Sussex, SPRU, UK and Bocconi University, IT
Knowledge Accumulation, Regulation, and Appropriability in Europe's Pharmabiotech Industry

- 17.05-17.40 **Koen Wiedhaup**
Netherlands Genomics Initiative, NL
Public and Private Sector Interaction in Promoting Biomedical Innovation
- 17.40-18.10 **Timm-H. Jessen**
Bionamics GmbH, Kiel, DE
Session Discussion on The Fragile State of Europe's Biomedical Industry
- 19.00 Dinner

Sunday – October 7

Session 5: Health Care Institutions, Investment Incentives, and the Diffusion of Innovations

Chair: M.N. Graham Dukes, University of Oslo, NO

- 09.15-09.55 **Yelzhan Birtanov**
Institute for Healthcare Development, Almaty, KZ
Ensuring Therapeutic Advance in a Transitional Economy
- 09.55-10.35 **Ramanan Laxminarayan**
Resources for the Future, Washington DC, US
Antimicrobial Drug Resistance: An Agenda for Research and Policy
- 10.35-11.10 Coffee break
- 11.10-11.30 **Samira Humaira Habib**
University of Dhaka, BD
Cost-effectiveness Analysis of Medical Intervention in Patients with Early Detection of Diabetic Foot in a Tertiary Care Hospital in Bangladesh
- 11.30-11.50 **Alireza Haghighi**
University of Oxford, Nuffield Department of Clinical Medicine, UK
The Role of Diaspora in Medical Knowledge and Technology Transfer to Developing Countries – A Network Model
- 11.50-12.10 **Nicola Leaney**
Phoenix Biologix Pty Ltd, Broadway, AU
Sustainable Manufacturing for Developed Countries – How to Cooperate with Emerging Economies

12.10-12.30	Wolf Rogowski GSF National Research Centre for Environment and Health, Neuherberg, DE <i>Key Features for Monitoring and Comparing Fourth Hurdle Institutions</i>
12.30-14.00	Lunch
14.00-14.40	Peter Zweifel Socioeconomic Institute, University of Zürich, CH <i>The Influence of Insurance on Biomedical Innovation</i>
14.40-15.00	Alexander Jean Luc Coad Max-Planck-Institute of Economics, Jena, DE <i>The Co-Evolution of Sales Growth, Employment Growth and Growth of R&D Expenditure</i>
15.00-15.20	Pedro Luis Sanchez Farmaindustria, Madrid, ES <i>Prices and Penetration of Pharmaceutical Innovations – An International Comparison</i>
15.20-15.45	t.b.a. <i>Session Discussion on Health Care Institutions, Investment Incentives, and the Diffusion of Innovations</i>
15.45-16.00	Coffee break
16.00-17.00	Forward Look Plenary Discussion and Award of Best Poster Prize
17.00-18.00	Conference Closing Session
19.00	Conference Dinner

Monday – October 8

Departure after breakfast

Instructions

We plan for a full three-day program that avoids parallel sessions. All invited speakers should present their ideas and findings to the full plenum, with sufficient time for subsequent plenary discussions. In between, there will be poster sessions and outstanding junior scholars may be given the opportunity to give short oral presentations to the plenum.

There will also be time and space to meet informally in small groups in various rooms in the hotel or in the Kiel Institute and outside, in the extensive park or on the shore of the Kiel Fjord. Sailing boats will be available for rent.

This year's conference on „The Global Organization of Biomedical Innovation“ is the third event in the series known as the ESF-IfW Conferences on The Global Health Economy. It is supported by an academic advisory council that comprises leading scholars in the fields of medicine, health economics and related sciences and a number of leading representatives from German health care finance, industry and politics.

These include

- Ulrike Beisiegel, Director of the Institute for Biochemistry and Molecular Biology at the Eppendorf Research Hospital of the University of Hamburg,
- Norbert Klusen, Chairman of the Board of Techniker Krankenkasse, Hamburg, Germany's most innovative sickness fund,
- Hellmut Körner, Secretary of State for Social Affairs, Health, and Family Policy in Schleswig-Holstein,
- Heiner Raspe, Director of the Institute for Social Medicine at the Medical University of Lübeck,
- Wolfgang Reim, former President and Chief Executive Officer of Dräger Medical AG & Co. KG, a Dräger and Siemens Company, and Member of the Board of Drägerwerk AG, Lübeck,
- Ernst Theodor Rietschel, President of the Leibniz-Gemeinschaft, one of Germany largest research organizations with an extensive research portfolio in both medicine and economics and a total of 84 autonomous research institutes,
- Stefan Schreiber, Director of the Institute for Clinical Molecular Biology at the University of Kiel and Director of the German National Genome Research Network,
- J.-Matthias Graf von der Schulenburg, Director of the Institute for Insurance Economics and Director of the Research Center for Health Economics and Health Systems Research at the University of Hannover, and
- Dennis Snower, Ph.D., President of the Kiel Institute for the World Economy and Chair of the Department for Economic Theory at the University of Kiel.